Back

Cardiovascular outcomes of sodium glucose co-transporter-2 inhibitor treatment in cancer patients receiving anthracycline chemotherapy: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology: around the world Diagnosis and Management of Cardiovascular Disease in Patients with Cancer ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Rey Adam Cordovez

Vicente Sotto Memorial Medical Center, Cebu City (Philippines)

5 More presentations in this session

Presentation thumbnail
Prognostic value of asymptomatic coronary artery disease and coronary artery calcium score for the risk of cancer therapy-related cardiac dysfunction (ANTEC study)
Doctor A. Borowiec (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Temporal trends and outcomes of amyloidosis in Korea: a 13-year nationwide cohort study with a focus on cardiac involvement
Doctor M. Jung (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Echocardiographic assessment of early radiotherapy-induced cardiotoxicity in breast cancer patients
Assistant Professor M. Cvijic (Ljubljana, SI)
Abstract Slides Video
Presentation thumbnail
P-Selectin - predictor of venous thromboembolism in cancer patients?
Ms N. Diaconu (Chisinau, MD)
Abstract Slides Video
Presentation thumbnail
Endocarditis in patients with active malignant disease: a common condition with high rates of morbidity and mortality
Mr K. Rakhimov (Berlin, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology: around the world

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Sodium-glucose co-transporter-2 inhibitors : a potential cardioprotective agent?
thumbnail
Congress Presentation
The cardioprotective effect of inhibitor sodium glucose transporter in patients undergoing chemotherapy: a systematic review and meta-analysis
thumbnail
Congress Presentation
Anthracycline cardiotoxicity in patients receiving sodium-glucose co-transporter-2 inhibitors -is there any difference?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources